Niraparib maintenance after chemo and Avastin for advanced ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether the PARP inhibitor niraparib can help keep advanced ovarian cancer from coming back. You may qualify if you have a BRCA mutation or HRD-positive tumor and finished first-line chemotherapy with bevacizumab (Avastin) with good response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older
- You have advanced (stage III or IV) high-grade ovarian, fallopian tube, or peritoneal cancer
- You had surgery for your cancer and then received at least 2 cycles of bevacizumab (Avastin) with platinum-based chemotherapy
- Your cancer responded (complete or partial) to that chemotherapy, and your CA-125 level is normal or dropped by at least 90%
- A genetic test shows your tumor is HRD-positive or has a BRCA mutation
- You start treatment within 12 weeks after finishing chemotherapy, and your blood counts and organ function are adequate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether niraparib works better when combined with bevacizumab after chemotherapy and surgery for advanced ovarian, fallopian tube, or peritoneal cancer. If you qualify, you may help researchers find a treatment plan that controls the cancer for longer.
This trial tests whether niraparib, taken after surgery, works better when combined with bevacizumab in people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have no visible tumor left. It also aims to see if this approach helps prevent the cancer from coming back.
This study looks at how well the drug niraparib works as a maintenance treatment for women with advanced ovarian cancer that responded well to initial platinum-based chemotherapy. It may help keep the cancer from coming back.
This trial checks the safety of niraparib, a targeted therapy that may help keep ovarian cancer from coming back after chemotherapy. It is for women whose cancer has responded to platinum-based chemotherapy, either as first treatment or after a relapse.
This trial tests a combination of two targeted drugs, niraparib and abemaciclib, for people with ovarian, fallopian tube, or primary peritoneal cancer that has come back after at least two prior chemotherapies. It may be an option if you have no standard treatments left and your cancer still responds to platinum-based chemotherapy.
This study looks at how well niraparib works as maintenance therapy for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have already responded to initial chemotherapy. It aims to gather real-world data on the treatment's effectiveness and safety.
Hear when a new Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.